Table 3 Relevant section from WHO guidelines on G6PD testing for PQ based radical cure [8]

The G6PD status of patients should be used to guide administration of PQ for preventing relapse. Good practise statement

Executive summary—page 11

Treatment of uncomplicated malaria caused by P. vivax, P. ovale, P. malariae or P. knowlesi—page 60

When G6PD status is unknown and G6PD testing is not available, a decision to prescribe PQ must be based on an assessment of the risks and benefits of adding PQ. Good practise statement

Executive summary—page 11

Treatment of uncomplicated malaria caused by P. vivax, P. ovale, P. malariae or P. knowlesi—page 60

Given the benefits of preventing relapse and in the light of changing epidemiology worldwide and more aggressive targets for malaria control and elimination, the group now recommends that PQ be used in all settings

Treatment of uncomplicated malaria caused by P. vivax, P. ovale, P. malariae or P. knowlesi—page 68

In the absence of quantitative testing, all females should be considered as potentially having intermediate G6PD activity and given the 14-day regimen of PQ, with counselling on how to recognize symptoms and signs of haemolytic anaemia

Treatment of uncomplicated malaria caused by P. vivax, P. ovale, P. malariae or P. knowlesi—page 69

If G6PD testing is not available, a decision to prescribe or withhold PQ should be based on the balance of the probability and benefits of preventing relapse against the risks of PQ induced haemolytic anaemia. This depends on the population prevalence of G6PD deficiency, the severity of the prevalent genotypes and on the capacity of health services to identify and manage PQ induced haemolytic reactions

Treatment of uncomplicated malaria caused by P. vivax, P. ovale, P. malariae or P. knowlesi—page 69